Updates to AIM Specialty Health Radiation Oncology Clinical Appropriateness Guidelines
- Radiation Therapy — Updates by section
- Gastrointestinal (GI) Cancers — Intensity modulated radiation therapy (IMRT)
- Removed plan comparison requirement for cholangiocarcinoma, esophageal, gastric, hepatocellular, and pancreatic cancer, because IMRT has become standard of care for curative treatment of these GI malignancies
- Oligometastatic Extracranial Disease — SBRT: stereotactic body radiation therapy (SBRT)
- Added indication for adrenal metastases as SABR-COMET trial listed this as one of the most common sites treated in that trial
- Prostate Cancer — Brachytherapy:
- Added indication for high-dose rate monotherapy in low- and intermediate-risk disease
- Image Guidance radiation therapy (IGRT)
- Added surface-based guidance technique (no change in intent or coding)
- Added statement that IGRT is not medically necessary to guide superficial radiotherapy for non-melanoma skin cancer (supported by American Society for Radiation Oncology [ASTRO] Clinical Practice Guideline)
As a reminder, ordering and servicing providers may submit prior authorization requests to AIM through the AIM ProviderPortalSM directly at www.providerportal.com.
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
For questions related to guidelines, please contact AIM via email at email@example.com. Additionally, you can access and download a copy of the current and upcoming guidelines here.
January 2023 Provider Newsletter - New Hampshire